Evaluating the bioequivalence of levetiracetam brand and generic oral tablets available in the Saudi market in vivo.

ABSTRACT:

Background

Epilepsy is a common global neurological disorder. About 30% of epileptic patients are managed with anti-epileptic Drugs (AEDs). Since 2000, Levetiracetam (LEV) has been marketed around the world as an AED under the brand name Keppra, and recently more generics are found in the Saudi market as cheaper alternatives. The objective of this study is to evaluate the bioequivalence of LEV brand and generics available in the Saudi market in mice.

Methods

Pharmacokinetics (PK), liver function test, and behavioral studies were conducted for LEV brand and generic in different groups of Blab/c mice.

Results

PK results show a significance difference in PK parameters mostly evidenced with generic 3, then generic 2. The only significant different between Keppra and gener

SUBMITTER: ALRabeeah D 

PROVIDER: S-EPMC10518482 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature